EXHIBIT 10.6 Letter of Intent with Oncology Sciences Corporation,
             November 6, 2003


                                November 6, 2003



Dr. Tony Milici GeneThera, Inc.
3930 Youngfield Street
Wheatridge, CO 80033


Dear Dr. Milici:

     This letter evidences Oncology Sciences Corporation's (OSC) intent to enter
into a business agreement with GeneThera, Inc. (GTHA) to develop tumor marker
p65 diagnostic tests. The ultimate goal of this relationship is to develop two
assays in parallel: one ELISA-based and one real-time PCR based. The mutual
desire is to sell test kits (ELISA) to the research community to perform assays
on-site and to offer real-time PCR assays at GTHA (and/or at a to-be-determined
partner CLIA lab) on a fee-for-service basis. OSC will aid, ultimately, in the
marketing of such tests. Data for FDA approval will also be acquired and
compiled during the process.

     For the next 30 days, GTHA will, at its expense, and with the help of Drs.
Slaga and Hanausek, perform certain experiments with the real-time PCR system
using whole-blood samples and cell culture samples to assess feasibility of
building an assay system with other GTHA technology.

     During this period GTHA will also gather information from its target
investment community as to whether this development project between the
companies will generate financial interest and thereby result in investment in
GTHA. The resulting investment would be used by GTHA to pay OSC a license fee;
to pay the necessary development costs for AMC Cancer Research Center (through a
sponsored research agreement with OSC and AMC); to pay other related development
costs for GTHA; to seek an OEM manufacturing company for the ELISA kit; and to
seek CLIA lab acquisition or partnership opportunities.

     OSC warrants that is the exclusive licensee of United States Patents
     5,310,653, 5,411,868, and 5,773,215 (the "p65 technology"). OSC agrees to
     maintain its rights with the licensor of the p65 technology during the
     option period of 30 days.

     It is specifically understood by the parties hereto that this is only a
letter of intent and is not the actual contract for licensing and subsequent
development of the p65 assays. If the scientific outcome and the financial
interest-screening outcome are both favorable, then GTHA and OSC will attempt to
enter into an agreement which may or may not include, among other things, the
following:

     o    GTHA will seek a to-be-determined amount in investment for this
          project
     o    OSC will grant GTHA a sublicense to the p65 technology, subject to the
          terms and conditions of the license agreement governing OSC's rights
          to the p65 technology
     o    GTHA shall pay OSC a license fee payment of 200,000 shares of GTHA
          common stock
     o    GTHA will pay OSC $250,000 over a 12 month period for the ELISA
          development - to be used by OSC in a sponsored research agreement with
          AMC
     o    GTHA shall invest a to-be-determined amountin real-time PCR assay
          development for the p65 technology
     o    GTHA shall invest a minimum of $100,000 to work on manufacturing/scale
          up with partner for commercialization of ELISA kits (format, labeling,
          instructions, etc.)
     o    GTHA shall invest a minimum of $150,000 for marketing and training
          materials for commercialization of both tests
     o    OSC and GTHA will agree to a to-be-determined profit split upon
          commercialization of the kits
     o    In the event new intellectual property is developed (e.g. a rnai
          therapeutic), such inventions will be owned jointly by OSC and GTHA.

<PAGE>

Please contact me if you have any questions.

                                      Sincerely,


                                      Alan D. Andrews,
                                      Vice President



Please indicate your agreement to the terms of this letter of intent with your
signature below:

Dated:   November _______, 2003

By:___________________________
Dr. Tony Milici, President
GeneThera, Inc.